Who we are
BioCurate’s mission is to identify promising biomedical research discoveries and advance their translation into high-quality pre-clinical candidates for novel human therapeutics. BioCurate was jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government. BioCurate is operationally independent, with a team of experts who bring decades of scientific and commercial expertise, enabling BioCurate to recognise and realise real-world potential and provides a critical bridge between academia and industry within the biotechnology sector to accelerate the development of new therapies. BioCurate leverages an extensive global network of partners and collaborators to deliver the effective commercial pathways for Australian innovation.
We bridge the gap
Our collaborative team of global biomedical experts bridge the gap between:
Academia + Industry
Ideas + Impact
Focus + Collaboration
Collaboration + Commercialisation
Research + Translation
What we are doing
The BioCurate team
Meet Chacko Joseph
Head of Drug Development
Dr Chacko Joseph is a seasoned life sciences professional with over a decade of experience in early-stage drug development, technology transfer, and strategic partnerships.
Read more about Chacko
Meet our team
Meet Jaclyn Sceneay
Director of Biology
Dr Jaclyn Sceneay is an immuno-oncologist with experience in small molecule and PROTAC drug discovery, and microbiome therapeutics.
Read more about Jaclyn
Meet our team
Our team
170
More than 170 years of combined biotech/pharma industry experience
13
Directly involved in over 13 Investigational New Drug applications (INDs)
30
Responsible for 30 therapeutics currently in the clinic
$2.4B
Directly involved in deals worth a cumulative total of more than $2.4 billion
Professor Roger Daly, Head of the Signalling Network Laboratory, Monash Biomedicine Discovery Institute
“They [BioCurate] change your way of thinking as an academic researcher. They [BioCurate] highlight things which are really critical to potential commercialisation of a project, which you may not have thought of.”
Dr Linda Pullan, Director, Pullan Consulting, CA, USA and member of ISAG
“BioCurate brings deep industry perspective to select opportunities most likely to appeal to biotechnology and pharmaceutical companies, to confirm or extend the properties essential to entice those partners, and to communicate the science in a way that enables ready assessment of fit. This is hugely valuable to industry licensing efforts and will increase the probability of commercialization of the academic work.
I expect BioCurate to be on the top of the list of places where industry will hunt for early drug candidates.”
Professor Christoph Hagemeyer, Monash University
“We are very excited to bring our novel antibody from the bench closer to the bedside with help from the great team at BioCurate and make an impact in the cardiovascular disease indication. Our antibody targets a never before explored thrombotic mechanism that can potentially provide anti-thrombotic therapy without adverse effects.”
Penelope Lane, Senior Business Development Manager, the University of Melbourne
“Working with the team at BioCurate towards translation and commercialisation of medical research from the University of Melbourne has been a comprehensive, professional and considered experience, allowing the researchers, commercialisation teams and funds to successfully navigate investment into early stage medical research.
Collaboration of this nature is a best practice example in support of a truly innovative ecosystem for medical research.”
Professor Roger Daly, Head of the Signalling Network Laboratory, Monash Biomedicine Discovery Institute
“They [BioCurate] change your way of thinking as an academic researcher. They [BioCurate] highlight things which are really critical to potential commercialisation of a project, which you may not have thought of.”
Dr Linda Pullan, Director, Pullan Consulting, CA, USA and member of ISAG
“BioCurate brings deep industry perspective to select opportunities most likely to appeal to biotechnology and pharmaceutical companies, to confirm or extend the properties essential to entice those partners, and to communicate the science in a way that enables ready assessment of fit. This is hugely valuable to industry licensing efforts and will increase the probability of commercialization of the academic work.
I expect BioCurate to be on the top of the list of places where industry will hunt for early drug candidates.”
Professor Christoph Hagemeyer, Monash University
“We are very excited to bring our novel antibody from the bench closer to the bedside with help from the great team at BioCurate and make an impact in the cardiovascular disease indication. Our antibody targets a never before explored thrombotic mechanism that can potentially provide anti-thrombotic therapy without adverse effects.”
Penelope Lane, Senior Business Development Manager, the University of Melbourne
“Working with the team at BioCurate towards translation and commercialisation of medical research from the University of Melbourne has been a comprehensive, professional and considered experience, allowing the researchers, commercialisation teams and funds to successfully navigate investment into early stage medical research.
Collaboration of this nature is a best practice example in support of a truly innovative ecosystem for medical research.”